Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 10, 2021

SELL
$14.07 - $17.3 $751,366 - $923,854
-53,402 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$15.15 - $19.78 $752,924 - $983,026
-49,698 Reduced 48.2%
53,402 $923,000
Q4 2020

Feb 11, 2021

SELL
$16.86 - $19.67 $264,702 - $308,819
-15,700 Reduced 13.22%
103,100 $1.9 Million
Q3 2020

Nov 12, 2020

BUY
$15.4 - $20.16 $93,940 - $122,976
6,100 Added 5.41%
118,800 $2.06 Million
Q2 2020

Aug 13, 2020

BUY
$18.24 - $21.45 $302,784 - $356,070
16,600 Added 17.27%
112,700 $2.06 Million
Q1 2020

May 13, 2020

SELL
$16.28 - $25.63 $198,616 - $312,686
-12,200 Reduced 11.27%
96,100 $1.94 Million
Q4 2019

Feb 14, 2020

SELL
$19.57 - $23.52 $144,818 - $174,048
-7,400 Reduced 6.4%
108,300 $2.52 Million
Q3 2019

Nov 08, 2019

SELL
$19.85 - $22.76 $208,425 - $238,980
-10,500 Reduced 8.32%
115,700 $2.32 Million
Q2 2019

Aug 09, 2019

SELL
$17.59 - $21.1 $728,226 - $873,540
-41,400 Reduced 24.7%
126,200 $2.66 Million
Q1 2019

May 15, 2019

BUY
$18.01 - $20.11 $237,732 - $265,452
13,200 Added 8.55%
167,600 $3.37 Million
Q4 2018

Feb 12, 2019

SELL
$17.44 - $21.53 $270,320 - $333,715
-15,500 Reduced 9.12%
154,400 $2.84 Million
Q3 2018

Nov 05, 2018

BUY
$19.97 - $21.96 $790,812 - $869,616
39,600 Added 30.39%
169,900 $3.63 Million
Q2 2018

Aug 14, 2018

SELL
$20.16 - $24.68 $268,128 - $328,244
-13,300 Reduced 9.26%
130,300 $2.8 Million
Q1 2018

Apr 30, 2018

SELL
$20.31 - $24.95 $266,061 - $326,845
-13,100 Reduced 8.36%
143,600 $3.04 Million
Q4 2017

Feb 12, 2018

SELL
$20.99 - $23.89 $749,343 - $852,873
-35,700 Reduced 18.56%
156,700 $3.59 Million
Q3 2017

Nov 13, 2017

BUY
$20.07 - $21.89 $228,798 - $249,546
11,400 Added 6.3%
192,400 $4.21 Million
Q2 2017

Aug 14, 2017

BUY
N/A
181,000
181,000 $0

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.48B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Skandinaviska Enskilda Banken Ab (Publ) Portfolio

Follow Skandinaviska Enskilda Banken Ab (Publ) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

News

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.